PRAMEF22: A Potential Drug Target and Biomarker for Cancer (G653606)

Target Name: PRAMEF22

NCBI ID: G653606

Other Name(s): PRA22_HUMAN | PRAME family member 22 | PRAMEF3L

PRAMEF22: A Potential Drug Target and Biomarker for Cancer

PRAMEF22 is a protein that is expressed in human tissues and has been identified as a potential drug target in the treatment of various diseases, including cancer. The protein is derived from the human proteasome, which is a complex of proteins that are involved in the breakdown of cellular components.

The human proteasome is a key regulator of protein synthesis and degradation, and it is involved in the control of a wide range of cellular processes, including cell growth, differentiation, and response to stimuli. PRAMEF22 is a member of the PRAMEF family of proteins, which are characterized by the presence of a specific domain known as the N-terminal hypervariable region (HVR).

The N-terminal HVR is a region of the protein that is highly variable and can be modified by various chemical modifications, such as phosphorylation, acetylation, and ubiquitination. PRAMEF22 has been shown to have multiple functions in cellular processes, including cell adhesion, migration, and invasion.

In addition to its functions in cellular processes, PRAMEF22 is also a potential drug target. Its N-terminal HVR is thought to be involved in the regulation of cellular interactions with other proteins and molecules, and this may make it a useful target for small molecules that can modulate these interactions.

One of the potential benefits of targeting PRAMEF22 is its potential to act as a biomarker for various diseases. Its expression is known to be elevated in a variety of cancer types, including breast, ovarian, and colorectal cancers. This makes it a potential target for cancer therapies that can inhibit its activity.

Another potential benefit of PRAMEF22 is its role in cell signaling. Its N-terminal HVR is involved in several signaling pathways that are involved in cellular processes, including the regulation of cell growth, differentiation, and survival. This suggests that targeting PRAMEF22 may be a way to disrupt these signaling pathways and have negative effects on cellular processes that are associated with the development and progression of cancer.

In conclusion, PRAMEF22 is a protein that is expressed in human tissues and has been identified as a potential drug target in the treatment of various diseases. Its N-terminal HVR makes it a potential target for small molecules that can modulate its activity, and its role in cell signaling may make it a useful target for therapies that can disrupt its function in the regulation of cellular processes that are associated with cancer. Further research is needed to determine the full potential of PRAMEF22 as a drug target and its potential as a biomarker for various diseases.

Protein Name: PRAME Family Member 22

More Common Targets